Phase 2 N=119 Resveratrol for Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Adverse Events — 355; 302 number of AEs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=241 A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)
Kidney Disease, Chronic
Primary: Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Modification of Diet in Renal Disease With 4 Variables (MDRD-4) — 3.04; 0.82…
Phase 2 N=20 Vitamin D to Prevent Autism in Newborn Siblings
Autistic Disorder
Primary: Number of Children Who Developed Autism — 1 Children who developed autism
Phase 4 N=32 Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Rupture
Primary: Change in Numerical Rating Scale (NRS) Pain Score — 3.6; 4.7; 5.0; 4.1 units on a scale
N/A N=221 Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens
Refractive Error
Primary: Slit Lamp Findings — 3; 2 Eyes
Phase 3 N=25 A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE) — 25; 25; 22; 21 participants
Phase 2 N=17 A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Thrombocytopaenia
Primary: Number of Participants With Platelet Response up to Week 8 During Part 1 — 4 Participants
N/A N=191 Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
Psoriasis
Primary: Adalimumab Treatment Retention Status — 44.0; 2.6; 8.4; 38.7 percentage of participants
Phase 3 N=3,590 A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
Meningococcal Vaccine
Primary: Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit…
Phase 2 N=61 Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Response Rate (ORR) — 6.9 percentage of participants
Phase 4 N=896 A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response According to Scheduled Treatment Period — 53; 50 percentage of participants — p=0.2893
Phase 4 N=136 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
Colon Cancer
Primary: Boston Prep Scale — 7.0; 7.2 units on a scale — p=.45
Phase 1 N=39 Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) (Single Dose) — 1.920; 3.830 nanograms per milliliter (ng/mL)
N/A N=44 The Effects of Dexmedetomidine and Propofol on Cerebral Blood Flow and Brain Oxygenation During Deep Brain Stimulation
Intracranial Neurosurgery
Primary: Cerebral Blood Flow — 45.4; 39.9 cm/sec — p=0.011
Phase 3 N=30 Cholecalciferol Supplementation for Sepsis in the ICU
Hypovitaminosis D
Primary: Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol — 19; 15; 17; 19 ng/mL